FLT3 and neoplasm: Sorafenib, firstly known for its antiangiogenic effect and approved for treating HCC, RCC and DTC, is found potent in inhibiting FLT3, with a significant anti-tumor effect in the FLT3-ITD mutant AML (11–13).